Half-life of single-chain urokinase-type plasminogen activator (scu-PA) and two-chain urokinase-type plasminogen activator (tcu-PA) in patients with acute myocardial infarction.
The pharmacokinetics of urokinase (two-chain urokinase-type plasminogen activator, tcu-PA) and single-chain urokinase-type plasminogen activator (scu-PA) were studied in 20 patients with acute myocardial infarction (AMI). Ten consecutive patients received 2.5 million units tcu-PA by bolus injection within 5 min during the first 6 h after AMI (group I). Ten further consecutive patients received 250,000 U tcu-PA within 5 min, followed by 4.5 million U scu-PA by intravenous infusion over 40 min (group II). An enzyme immunoassay was developed for urokinase antigen determinations, and a fibrin plate assay for determinations of fibrinolytic activity was applied. Using a 3-compartment model, in group I 98% of urokinase antigen were cleared with a half-life of 60.8 min. After scu-PA, urokinase antigen was cleared with half-lives (area under the curve in parentheses) of 6.9 min (74.8%), 26.5 min (23.6%), and 329.7 min (2.2%). The half-disappearance times of fibrinolytic activity were 18 and 8 min in group I and II, respectively. A more pronounced decrease of plasminogen was observed after tcu-PA.
Köhler
M
M
Department of Clinical Haemostaseology and Transfusion Medicine, University of Saarland, Homburg, F.R.G.
Sen
S
S
Miyashita
C
C
Hermes
R
R
Pindur
G
G
Heiden
M
M
Berg
G
G
Mörsdorf
S
S
Leipnitz
G
G
Zeppezauer
M
M
D006207:Half-Life; D006801:Humans; D008875:Middle Aged; D008970:Molecular Weight; D009203:Myocardial Infarction / Q000188:drug therapy / Q000378:metabolism*; D010960:Plasminogen Activators / Q000493:pharmacokinetics* / Q000627:therapeutic use; D014568:Urokinase-Type Plasminogen Activator / Q000493:pharmacokinetics* / Q000627:therapeutic use
D010960:Plasminogen Activators; D014568:Urokinase-Type Plasminogen Activator